Latest News

3/20 Taiwan Life Sciences Biweekly Newsletter

Taiwan Life Sciences Biweekly
Meet Erik Ramp of Edwards Lifesciences
Interview with Edwards Lifesciences Taiwan Managing Director Erik Ramp
15 March, 2023
Erik Ramp, senior director and general manager of Edwards Lifesciences Taiwan, leverages his diverse professional experience to accelerate patient access to critical care and cardiovascular medical devices. His influential leadership style, curious mindset, and problem-solving abilities have helped him overcome adversity and lead teams to success in the U.S., China, Malaysia, and Taiwan. More...
Hospital touts new world-class center for surgical training
15 March, 2023
Linkou Chang Gung Memorial Hospital's newly completed Surgical Skills Training and Research Center would boost healthcare quality and attract medical students from around the world, the hospital said yesterday. More...
Zuellig Pharma Celebrates a Century of Making Healthcare Accessible
Interview with Zuellig Pharma Taiwan Managing Director John Chou
14 March, 2023
During its 100-year history, Zuellig Pharma has grown from a domestic distributor to one of the largest healthcare services groups in Asia. The company now provides distribution and digital and commercial services covering nearly 350,000 clinics, hospitals, pharmacies, and modern trade outlets. More...
Taiwan's DCB licensed its ADC technology for a record NT$690 million
14 March, 2023
The Ministry of Economic Affairs (MOEA) announced on the 13th that the ADC (Antibody Drug Conjugate) technology, pioneered by the Development Center for Biotechnology (DCB), has been transferred to HoneyBear Biosciences, a company invested by SCI Pharmtech Inc., with a total licensing amount of NT$690 million, a new record for DCB technology transfer. More...
Taiwan's pharmaceutical companies to fill the gap in rare disease drugs market
13 March, 2023
Annji Pharmaceutical's licensing agreement up to $250 million with US-based Avenue Therapeutics to develop and commercialize AJ201 for a rare disease has become the talk of the town, which fueled more discussions amongst Taiwanese pharmaceutical companies that have orphan drug approvals. More...
GaleMed's MDR certification eases access to European market
8 March, 2023
Reforms to the EU掇 medical device laws came into force on May 26, 2021, as the previous Medical Devices Directives (MDD) were upgraded to the more stringent and legally binding Medical Devices Regulation (MDR). This reform has greatly raised the threshold for medical devices to gain access to the EU market. It also makes the application process more difficult and requires more time for preparation. More...
Linkou Chang Gung world's second highest ranked smart hospital: HIMSS
7 March, 2023
Linkou Chang Gung Memorial Hospital was selected by the "Health Information and Management System Society" (HIMSS) in its evaluation of digital healthcare indicators as the second highest ranked smart hospital in the world, and the first in Taiwan. Cheng Wenjun, the chairman of the Chang Gung Policy Committee, reflecting on this recognition by HIMSS, said that he expects Linkou Chang Gung to become the new benchmark of international smart medical care.

HIMSS is the abbreviation of Society for Medical Information and Management Systems, founded in 1961 and headquartered in Chicago, USA. It is a global non-profit organization whose purpose is to improve medical standards through information technology. Its 'Digital Healthcare Indicators' evaluation includes four categories: "Information Interoperability", "People-oriented Health Care", "Predictive Analysis", and "Governance and Labor" to evaluate the degree of intelligence of global medical institutions. More...
IND approved for antibody drug AM-928 for treatment of solid cancers
6 March, 2023
AcadeMab Biomedical, founded in 2020 to develop antibody drug authority Wu Hanzhong's research, announced that the IND application for its new antibody drug AM-928 IND had been approved by the US FDA, with Phase I clinical trial for patients with advanced solid cancers being to begin soon.

Wu is currently director of the Biomedical Translation Research Center of Taipei's National Biotechnology Research Park. AM-928 is a first-in-class monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM). More... (in Chinese)
Alar Pharmaceuticals' announces out licensing deal for its long-acting new drug addiction
6 March, 2023
Alar Pharmaceuticals (TW: 6785) announced that for the first time its long-acting injectable new drug ALA-1000 for drug addiction had received success in markets other than China, Hong Kong, Macau, and Taiwan, out licensing the drug to an unnamed major international pharmaceutical company, with the first milestone payment of US$5 million (approximately NT$153 million) already awarded. More... (in Chinese)
Industrializing iPSC and Harnessing its Medical Applications ?An Interview with Dr. Hong-Lin Su
6 March, 2023
Featured in the special topic of Gene and Cell Therapy, GeneOnline is honored to interview Professor Hong-Lin Su from the Department of Life Sciences at National Chung Hsing University, who is one of the few induced pluripotent stem cell (iPSC) experts in the field of cell therapy in Taiwan, with experience in academia, industry, and clinical practice. More...
Panion & BF Biotech's Phase III clinical trial data for kidney treatment unblinded successfully
6 March, 2023
Panion & BF Biotech has benefited from the increase in the profit of its nephropathy drug Naprofos. After reaching a new high in revenue last year, the company announced that the drug has a new dosage form and a new indication for iron deficiency anemia. With data from Phase III clinical trials in Taiwan successfully unblinded, there is a significant difference between the primary and secondary efficacy indicators. As such the company expects to apply for Taiwan drug approval and health insurance approval in the near future. Around 70 percent of patients undergoing kidney dialysis have hyperphosphatemia and iron deficiency anemia concurrently, with about 30 to 40 percent of patients with chronic kidney disease (non-dialysis) suffering also from iron deficiency anemia. Panion & BF Biotech's Nathophos have been expanded to renal and non-renal indications, and is currently sold in US and Japanese markets. It is currently the only treatment in the world that can simultaneously treat hyperphosphatemia and iron deficiency anemia in kidney disease patients. More... (in Chinese)
AnnJi Pharmaceutical's rare disease drug AJ201 out-licensed for US$250 million
4 March, 2023
AnnJi Pharmaceutical announced that its new small molecule drug AJ201 for the treatment of the rare disease Jackedy's disease was out-licensed to Nasdaq-listed Avenue Therapeutics in the United States for US$250 million (over NT$7.5 billion). Avenue Therapeutics expects the drug to book strong sales in European and American markets in the future. This licensing deal is reportedly the second highest in Taiwan's biotechnology deal history, second only to the US$530 million for Oneness Biotech's new allergic asthma drug FB825. The largest authorization case for a new drug for rare diseases in recent years, it is Taiwan's first licensing case this year.

AJ201 was acquired by Annji Pharmaceutical in 2021 at a price of NT$240 million through a share exchange with Allianz Biotechnology. As a result, it took only one and a half years of development to dramatically increase its value to US$250 million. More...
Taiwan Bio Industry Organization (Taiwan BIO)
Contact: Daisy Tsai
Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027
Mobile: +886 933-139647 | Line ID : daisy222

BIO Asia-Taiwan July 26-30, 2023

Taiwan Bio Industry Organization (TBIO)
Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd.,
Nangang Dist., Taipei, Taiwan (11571)
BIO Asia–Taiwan 2023 Onsite+Online